Verani and her sister Pharna
seen from United States

seen from Germany
seen from Malaysia
seen from United States
seen from United States
seen from United States
seen from United States

seen from United States
seen from Singapore
seen from United Kingdom

seen from France
seen from Lithuania
seen from China
seen from United States
seen from United Kingdom
seen from United States
seen from Argentina

seen from Canada
seen from United States
seen from United States
Verani and her sister Pharna
humanformers tarnma
The Contract Manufacturing Services Market for Stem Cells is Expected to be Worth Over USD 2.5 Billion by 2030, Claims Roots Analysis
Advances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.
練習。こ汚くなったけど堪忍な…